Theravance Biopharma Inc. inked a definitive agreement with Royalty Pharma potentially worth more than $1.5 billion to sell through a subsidiary, Theravance Respiratory Co. LLC, its 85% interest in royalty rights to Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, GSK plc), a once-daily, single-inhaler triple therapy for chronic obstructive pulmonary disease and asthma.
Despite the growing concerns about the potential for the community spread of COVID-19 in the U.S., the FDA-FTC public workshop on competition in the biologics marketplace went ahead as scheduled March 9, playing to a full house with some audience members sitting in an overflow room. And all the invited speakers and people registered to speak during the open public hearing session showed up.